[Skip to Content]
[Skip to Content Landing]
JAMA Clinical Evidence Synopsis
January 26, 2016

Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis

Author Affiliations
  • 1Neuroepidemiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
  • 2Italian Cochrane Centre, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
  • 3Scientific Direction, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
JAMA. 2016;315(4):409-410. doi:10.1001/jama.2015.18984
Abstract

Clinical Question  What immunotherapies for multiple sclerosis are associated with the greatest benefit and highest risk of discontinuation due to adverse events in patients with relapsing-remitting multiple sclerosis?

Bottom Line  Alemtuzumab, natalizumab, and fingolimod were associated with the greatest benefit with regard to relapse prevention. Their association with prevention of disability worsening was unclear. Fingolimod was associated with a high risk of treatment discontinuation due to adverse events.

×